JP MORGAN/PUT/VERTEX PHARMACEUTICALS/390/0.1/17.01.25

JP MORGAN/PUT/VERTEX PHARMACEUTICALS/390/0.1/17.01.25 Stock

DE000JB95Z39

Real-time Bid/Ask 05:06:19 2024-07-05 EDT
0.89 ^EUR / 1.19 ^EUR	+16.85%

Current month	-1.11%
1 month	-22.61%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart VERTEX PHARMACEUTICALS INCORPORATED

Chart JP MORGAN/PUT/VERTEX PHARMACEUTICALS/390/0.1/17.01.25

Latest news about VERTEX PHARMACEUTICALS INCORPORATED

FDA Accepts Vertex Pharmaceuticals' New-Drug Application for Combination Therapy to Treat Cystic Fibrosis	07-02	MT
Vertex Gets Speedy FDA Review of Vanza Triple Cystic Fibrosis Therapy	07-02	DJ
Vertex Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, a Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	BU
Vertex Pharmaceuticals Incorporated Announces FDA Acceptance of New Drug Application for Vanzacaftor/Tezacaftor/Deutivacaftor, A Next-In-Class Triple Combination Treatment for Cystic Fibrosis	07-02	CI

More news

Quotes 5-day view

Date	Price	Change
24-07-05	0.88	-1.12%
24-07-04	0.89	+8.54%
24-07-03	0.82	-5.75%
24-07-02	0.87	-8.42%
24-07-01	0.95	+5.56%

Delayed Quote Börse Stuttgart

Last update July 05, 2024 at 04:22 am

More quotes

Static data

Product type	Warrants
Buy / Sell	PUT
Underlying	VERTEX PHARMACEUTICALS INCORPORATED
Issuer	J.P. Morgan
WKN	JB95Z3
ISIN	DE000JB95Z39
Date issued	2023-12-21
Strike	390 $
Maturity	2025-01-17 (197 Days)
Parity	10 : 1
Emission price	2.93 €
Emission volume	N/A
Settlement	Por diferencias
Currency	EUR

Technical Indicators

Highest since issue	3.65 €
Lowest since issue	0.82 €
Delta	-0.16x
Omega	6.763
Premium	19.44x
Gearing	42.17x
Moneyness	0.8293
Difference Strike	-80.28 $
Difference Strike %	-20.58%
Spread	0.3 €
Spread %	25.42%
Theoretical value	1.030
Implied Volatility	34.06 %
Total Loss Probability	77.14 %
Intrinsic value	0.000000
Present value	1.030
Break even	378.85 €
Theta	-0.04x
Vega	0.08x
Rho	-0.04x

Company Profile

Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases. Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).

Sector

More about the company

Ratings for Vertex Pharmaceuticals Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Consensus: Vertex Pharmaceuticals Incorporated

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

470.3 USD

Average target price

468.3 USD

Spread / Average Target

-0.43%

Consensus